Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

109.33
+0.42000.39%
Pre-market: 109.25-0.0800-0.07%05:39 EDT
Volume:9.88M
Turnover:1.08B
Market Cap:136.00B
PE:23.11
High:109.77
Open:108.40
Low:107.65
Close:108.91
Loading ...

Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc

Reuters
·
Yesterday

Gilead Sciences Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Yesterday

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-06-02

Reuters
·
02 Jun

Gilead Sciences (GILD) Gets a Hold from Truist Financial

TIPRANKS
·
02 Jun

Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study

MT Newswires Live
·
02 Jun

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)

TIPRANKS
·
02 Jun

Gilead’s Kite announces real-world safety, effectiveness of Yescarta

TIPRANKS
·
02 Jun

Gilead announces data on Trodelvy plus Keytruda

TIPRANKS
·
02 Jun

Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Reuters
·
01 Jun

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Reuters
·
01 Jun

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Reuters
·
31 May

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
31 May

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
30 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-29

Reuters
·
29 May

Gilead Sciences Inc. Stock Rises Tuesday, Still Underperforms Market

Dow Jones
·
28 May

Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

Reuters
·
24 May

Healthcare Stocks Are So Bad, They're Good. What to Buy Now. -- Barrons.com

Dow Jones
·
23 May

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial

MT Newswires Live
·
23 May

BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Reuters
·
23 May

Gilead announces ASCENT-03 study meets primary endpoint

TIPRANKS
·
23 May